InsidersTradesSigma
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Browse the detailed record of transactions filed by Gerngross Tillman U., Director. Director active across 2 companies, notably Adagio Therapeutics, Inc.. In total, 4 reports have been published. Activity tracked since 16 June 2022. The latest transaction was filed on 14 June 2023 (Attribution). Regulator: SEC (Form 4). All data is accessible without signup.
4 of 4 declarations
Tillman U. Gerngross is the Chief Executive Officer and Director at Adagio Therapeutics, Inc. and Alector, Inc. He leads the strategic and business operations of both companies, focusing on innovation in the biopharmaceutical sector. His leadership is essential in guiding the vision and growth of the companies.